In accordance with Open Payments (Sunshine Act) and state-specific regulations, healthcare prescribers from Minnesota, Vermont, Washington, D.C., Louisiana, New Jersey, and Nevada must comply with their respective state laws regarding participation in meal functions sponsored by a medical device company. These states may have restrictions or reporting requirements on accepting meals or other transfers of value. It is the responsibility of each healthcare provider to ensure their participation aligns with their state's compliance guidelines.
1. Roehrborn, Can J Urol 2017*§ 2. Mariados NF, Orio PF III, King MT et al. JAMA Oncol (2023).*§
*Study sponsored by Palette Life Sciences, now part of Teleflex.
§One or more authors have/had a financial relationship with Teleflex.
The UroLift™ System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men
45 years or older with prostates 100 cc. Contraindicated in men with current gross hematuria, urinary tract infection, urinary incontinence due to incompetent
sphincter, and urethral conditions that prevent device insertion. Most common side effects are temporary and include hematuria, dysuria, micturition urgency,
pelvic pain, and urge incontinence. Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual
results may vary. Visit urolift.com.
Barrigel™ rectal spacer is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and, in creating
this space, the intent is to reduce the radiation dose delivered to the anterior rectum. It is composed of biodegradable material and maintains space for the entire
course of prostate radiotherapy treatment and is intended to be absorbed by the patient’s body over time. It should only be administered by qualified and properly
trained physicians with experience in ultrasound guidance and injection techniques in the urogenital/pelvic area. Potential complications include but are not
limited to: pain associated with the injection; needle penetration or injection of Barrigel rectal spacer into the bladder, prostate, rectal wall, rectum, urethra, or
intravascularly; local inflammatory reactions; infection; urinary retention; rectal mucosal damage, ulcers, necrosis; bleeding; constipation; and rectal urgency.
Contraindicated in prostate cancer patients with clinical stage T4 disease. Individual results may vary. Visit barrigel.com.
The Barrigel and UroLift logos are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.
© 2026 Teleflex Incorporated. All rights reserved. Rx only. APM1452A Rev A
All speakers are paid consultants of Teleflex. Teleflex reports the value of payments and other transfers of value, including but not limited to the provision of meals, to U.S. Healthcare Providers, in compliance with federal and state transparency laws. This invite is for the intended recipient and should not be forwarded. Spouses and/or uninvited attendees are prohibited from attending. Teleflex, the Teleflex logo, Barrigel, the Barrigel logo, UroLift, and the UroLift logo are trademarks or registered trademarks of Teleflex.
